Deubiquitinase UCHL1 targeting as part of new combinatorial treatments for hepatocellular carcinoma: a preclinical assessment Ghent University
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. At diagnosis many patient tumors already are in an advanced stage for which no curative options exist. The current therapies such as sorafenib or anti-VEGF treatment (alone or in combination treatment) only extend the bad prognosis for these patients with a few months of average overall survival and induce severe side effects. New therapy options extending the life ...